• FBB December 2018 – Newsletter

    December 2018 – Newsletter
     
    This month of December will beautifully close 2018 with 2 featured companies:
    Aspen Biosciences, who is launching a new comprehensive tool for a through exploration of the Biotech market, called Pharm2Market.
    And the in Vivo division of PerkinElmer, with the IVIS in vivo imaging systems and Quantum microCT imaging systems, which are best in class preclinical instruments for robust translational research.
     
    Companies of the month
     
    Aspen Biosciences
               
    PerkinElmer
     

     
    Résultats de recherche d'images pour « Perkinelmer »
     
    Aspen Biosciences – Pharm2Market

     
    Aspen Biosciences is a research informatics company which provides software and services to support drug discovery organizations. Some of our previous projects include custom target-, assay-, and compound-management systems designed to meet the unique needs of our customers. We also provide technology selection and implementation services for electronic lab notebook (eLN), and Lab Information Management Systems (LIMS). We have experience implementing systems to support a variety of therapeutic classes including small molecule, antibodies & peptides, and cell-based therapeutics.
     
    Pipeline – Drug Discovery Portfolio & Project Management
    Over the years we’ve had frequent requests for help developing or integrating project management tools. The challenge for most pharmaceutical companies has been that off-the-shelf applications in this space lack direct support for the science behind drug discovery projects. Tools like Microsoft Project, Jira, SmartSheet, and Asana lack support for target, pathway and literature information. They have no support for meeting and decision tracking, and lack support for lessons learned. To address that, we’ve distilled conversations with dozens of project and scientific portfolio managers in biotech and pharmaceutical companies into a cloud-based application called Pipeline.
     
    Pipeline helps drug discovery companies answer questions like, “What drug targets and pathways are we working on”, “What is their role in a given disease”, “What recent discoveries have been made (literature searching)”, “Who’s working on the project (project tracking & dashboarding)”, “What tasks are they performing”, “What’s the current status of the project”, “Where are the results from that cell-based assay we screened last month”, “How is this project similar to the project we worked on 5 years ago”, “What did we learn from this project”, “What lessons did we learn from previous projects that we can apply to this project”.

     
     
    Pharm2Market – Connecting Drug Discovery Communities
    Pharm2Market is a new service that we’re launching to connect drug discovery startups to news, investors, partners and services to help advance their drug discovery programs.
     
    If you’re a founder, Pharm2Market can help you find investors, partners and services in your area. We also help you find the resources, everything from finding legal advice on company formation and IP, to finding lab space, lab instrumentation and reagents. We also connect you with resources like the French Bio Beach, and San Diego Venture Group to help expand your network and keep track of all the local networking and conference opportunities.
     
    If you’re a business development professional, Pharm2Market contains information on over 200 local drug discovery companies. We track the projects, targets, therapeutic areas and therapeutic classes, pathways, and clinical trials that companies are involved in. This makes it easier for you to identify potential partnering and licensing opportunities.
     
    If your company provides lab space, construction or facilities services, you can use Pharm2Market to identify companies in need of expanded lab space, or lab remodels. If you provide contract research or manufacturing services, Pharm2Market can help you identify customers with Phase 2 and 3 projects who need your services in order to complete their clinical trials.
     

     
    To learn more about us or start a conversation, visit us on our web site, or reach out to us on social media:
     
    Twitter: @AspenBio @Pharm2Market
    Email: info@aspenbiosciences.com

     

     
    PerkinElmer In Vivo Imaging
     
    Image Caption: “IVIS Spectrum 3D bioluminescence reconstruction shows precise localization of GL261-luc2 brain tumor using digital organ map.”

    PerkinElmer Inc, through its Discovery & Analytical Solutions business segment, provides a suite of in vivo imaging solutions (IVIS) comprising reagents, software and instrumentation.  This powerful suite of tools allows researchers to visualize cellular and biological functions as well as anatomical and physiologic changes non-invasively in whole, live animals. 

    Optical imaging
    PerkinElmer’s IVIS instrument platform boasts several models each with somewhat different features and benefits and each designed to fit within almost any research budget.

    PerkinElmer’s flagship IVIS instrument is the IVIS Spectrum.  The Spectrum is the most advanced optical imaging system on the market combining high throughput (2D) optical imaging and full tomographic (3D) optical imaging in one platform.  The IVIS Spectrum is capable of ultra-sensitive bioluminescent and fluorescent imaging.  Bioluminescent sensitivity is achieved by using a cooled (-90ºC) camera with large CCD chip area and low F-stop.  With an exquisite signal-to-noise ratio (SNR) better than any other instrument on the market, the IVIS Spectrum has even been shown capable of detecting as few as five cells subcutaneously in nude mice.  For fluorescence applications, the IVIS Spectrum employs an optimized set of high efficiency filters (400nm to 900nm) and patented spectral unmixing software algorithms which grant researchers the ability to image and quantify all commonly used fluorophores, including fluorescent proteins, dyes and conjugates. 
    Going beyond just 2D imaging, full tomographic (3D) optical imaging can also be achieved with the IVIS Spectrum.  This allows researchers to analyze 3D sources in an anatomical context and quantify the of number of cells and/or the dye concentration.  Additionally, the 3D optical data can be co-registered with other tomographic technologies such as MR, PET or CT through PerkinElmer’s LivingImage multimodality software module.
     
    MicroCT Imaging
    Preserving the historical sweet spot of microCT imaging, PerkinElmer’s Quantum GX2, is an excellent imager for studying bone in exquisite detail.  But, thanks to its unique flat panel CMOS detector and its cardiac and respiratory gating tools, the Quantum GX2 also excels at providing functional information, such as cardiac function estimation or perfusion, as well as other soft tissue applications.
     
    Image Caption: “Quantum GX2 image of a mouse heart scanned using a four minute gated scan with CT contrast.”
     
    As previously mentioned, microCT has historically and primarily been used as a tool for capturing bone and skeletal image data, but bone data analysis was tedious and cumbersome.  To rectify this, scientists at PerkinElmer built AccuCT—a one-of-a-kind advanced, automated bone analysis software tool.  Designed to automatically segment bones and perform ASBMR morphometric analysis, AccuCT enables researchers at all levels of experience to perform advanced bone analysis in a user-friendly workflow-based software package.  In addition to facilitating data analysis, AccuCT’s 3D rendering capabilities produce high impact images for manuscripts and presentations with just a few mouse clicks. 
     
    Image Caption: “AccuCT from PerkinElmer automates bone identification, segmentation and analysis.”
     
    Through its advances in optical imaging and innovation with microCT imaging, PerkinElmer continues to open new doors for academic researchers and industry scientists alike.  Optical image data and microCT data can even be co-registered to better understand disease nuances in all its dimensions.
     
     
    To learn more about how in vivo imaging can help advance your research please contact your in vivo imaging specialist, Marc Guerra, at (619) 302-8405 or marc.guerra@perkinelmer.com

     
    Next Breakfast Event
     
    Because you are already sweet enough!
     
    Considering the significant increase of sugar consumption and commitments during the period of Christmas and New Year, the FBB committee board will hold on the Breakfast networking event until February.
     

     

     
    Happy Hour Networking Event
    bella vista social club & caffe
     
    December 14th
    from 5pm to 7pm (PST)
     
    Celebrating the end of the year. Come to tell us about your 2018 achievements and plan your 2019 expectations with a drink together.
     
     
     
     
     
    Social Activity
    Last chance to get your voice heard if you want to promote your favorite activities.
     
     
    First round of activity would open on Sunday, January 20, 2019 (10am-12pm).
    For now, six activities are leading the way: Hike, Surf, Pool (billiard), SUP/Kayak, Snorkeling, Tennis.

     

     
     
    Local News/Events
     
    Professional opportunities
    Antibody Design Labs is recruiting!
     
    We are looking for a part-time Office Assistant at our new location. The person will be in charge of diverse office clerk duties including helping with shipping and receiving, ordering and maintaining supply, managing files, recording information, greeting clients and visitors and coordinating team work and communication, among others. A strong organizational skill is welcome.
    Please send inquiry with resume at:  support@abdesignlabs.com
     
     
    We wish you happy holidays and hope to see you at our events!
    Kevin Adam, Beatrice David Shevlin and Stephane Richard of the French BioBeach team
    Follow our events and share to your friends/colleagues
     
             

     
    BECOME A
     
    OUR PARTNERS
     
    http://www.analytics-ventures.com/
     
     
     
     
     
     

     
    Thank You to our SPONSORS
    & MEMBERS
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Résultats de recherche d'images pour « Perkinelmer »
     
     
     
     
     
     
     

    Copyright © French BioBeach, All Rights Reserved.
     
    Business Platform, San Diego Area, California, United States
     
     
    Don't want this? Click here to unsubscribe.
     
     
     
    Ph: +1 (858) 215-2462 • www.frenchbiobeach.com
     
     
          
  • FBB November 2018 – Newsletter

    November 2018 – Newsletter
     
    After a month of October rich in networking events, November is following with the same momentum. Here are our news and activities for the upcoming month. In November our featured company is Cypre.
     
    Company of the month
    Cypre, Inc. has developed a simple 3D cell culture platform and tested protocols enabling scientists to assay complex tumor biology, including ex vivo (patient, PDX, mouse), tumor-stromal and tumor-immune coculture studies.

     

    VersaGel® is our proprietary, biocompatible 3D matrix that has the benefits of a hydrogel with the functional relevance of an extracellular matrix (ECM). Its design allows for cellular adhesion (through integrin binding sites, e.g. RGD), tumor and immune cell invasion, and MMP-degradation, mimicking the multiple phases of tumor progression.  VersaGel-Immunology is optimized for immune cell infiltration assays and VersaGel-Oncology, used in solid tumor assays, comes in three formulations for different growth conditions of various tumor cell types – Soft, Standard, Stiff. VersaGel is amenable to various methods of analysis, including high content imaging, plate reading, and flow cytometry following a 30-minute matrix digestion.
     
     
    Symphony® is our patented one-button instrument that solidifies VersaGel in microwell plates in 60 seconds. Symphony-24 and Symphony-96 are specifically designed for 24-well and 96-well plates respectively. Not much wider than a microtiter plate, the Symphony’s small footprint allows it to easily fit in your bio-safety cabinet further streamlining your workflow.
     
    Contact Robert Lynde (robert@cypre.co) to learn more about our demo program.
    Copyright© 2018 Cypre, Inc. All rights reserved.

     
    Next Breakfast Event
     
     
     

     

     

     
     
     
     
     
    Join us for a casual breakfast. This month Abbiotec will host the event. Abbiotec offers years of expertise making antibodies and assay kits for catalog products to the scientific and biotech community.
     
     
    When? Wednesday, November 7th
                from 8:00 to 9:30 am (PST)
     
    Where? 7985 Dunbrook Road,
    Suite A – San Diego, CA 92126
     

    Contact : (858) 586-0500  

     
    Happy Hour Networking Event
    bella vista social club & caffe https://ecp.yusercontent.com/mail?url=https%3A%2F%2Fcdn.evbuc.com%2Feventlogos%2F31248%2Fbellavista-2.jpg&t=1540866915&ymreqid=6ccb5610-53a0-1f6f-1c20-110001011c00&sig=unkBVS2esapgtA5MkKNLYg--~C
     
    November 9th
    from 5pm to 7pm (PST)
     
    Celebrating the Movember. Bring your most beautiful mustache to soak it in a drink together.
     
    All pattern are welcome!
     
     
     
     
    Social Activity
    Give us your opinion!
    The FBB community is growing and even if our common interests does not change, our way to interact can evolve. So let`s consider some activities together.
     
     
    Special Event
    Saturday, November 10th
     
    San Diego Fall Regatta 2018 – Sponsored by CureMatch
     
    If you wish to take advantage of this annual event to communicate/advertise about your company, we are currently open to distribute some goodies on the day of the event. Please contact the FBB Board of directors for any participation.
     
    Local News/Events
     
    We wish you a happy Halloween and hope to see you at our events!
    Kevin Adam, Beatrice David Shevlin and Stephane Richard of the French BioBeach team
    Follow our events and share to your friends/colleagues
     
             

     

     
    BECOME A
     
    OUR PARTNERS
     
    http://www.analytics-ventures.com/
     
     
     
     
     
     

     

     
    Thank You to our SPONSORS
    & MEMBERS
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Résultats de recherche d'images pour « Perkinelmer »
     
     
     
     
     
     
     

     

    Copyright © French BioBeach, All Rights Reserved.
    Business Platform, San Diego Area, California, United States
     
    Don't want this? Click here to unsubscribe.
     
    Ph: +1 (858) 215-2462 • www.frenchbiobeach.com
     
          
     
  • FBB November 2017 Newsletter





     
                 
                   
     
    Our newsletter keeps you in the loop of FBB’s News & Events. If for any reason you would like to  
    You are welcome to join us again at a later time
     
    BECOME A

     

     
    Thank You to our  Partners
     
     

    http://www.analytics-ventures.com/
     
     
     
     
     
     
     
     
     
     
     
     

     

    Big Thank You to our Sponsors & Members
     

     
     
     
     
     
     
     
     
     
     
     
     
     

     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     

     


     
    French BioBeach November 2017 Newsletter
     
       Dear French BioBeach community,
     
    After the success of the last month beakfast at Antibody Design, we are pleased to welcome you TOMORROW (Wednesday 1st) at ABBIOTEC jointly sponsored by ODDEXO. 
     
    To start this exciting newsletter we will present our FBB events with the traditional networking opportunities –> the Breakfast and the Happy Hour rendez-vous.
     
    Because to work hard we need to play hard sometimes, our new member SOMMAILLIER will present his concept of wine imported from France in the company of the month section, with an exclusive FBB discount just for you 🙂
     
    We end this newsletter by some events and news we thought you might enjoy!
     
    Thanks to your support, we continue to monitor what happens in the Life Sciences community fostering new Partnering and Business Opportunities.
    The French BioBeach Team  Cool
     
    Upcoming French BioBeach Events
     
     
    Coffee & Croissants
        
    The FBB Breakfast were traditionally on the first Tuesday of the month, but we thought that hump day will work even better!
    So from now on, you are welcome to join us on the first Wednesday of the month to share the yummy croissants and the much needed morning coffee 🙂
        
    When? Wednesday, November 1st from 8:00 am to 9.30 am

     

    Where?  Abbiotec  | 7985 Dunbrook Road | Ste A, San Diego | CA 92126

    abbiotec.com/contact/directions


     
     
     
     
     
     
     
     
     
     
    Monthly Happy Hour @ Bella Vista
     

    End of the week, Sunset & Happy Hour After Work? Let’s get together for our Monthly Networking Happy Hours. 
     
    We look forward to seeing you there…!

      
    When? Friday, November 10th, from 5:00 to 7:00pm

     

    Where?  Bella Vista Social Club & Caffe, 2880 Torrey Pines Scenic Dr, La Jolla, CA 92037 

    Look for our French BioBeach sign!

     

     
     
     
     
     
    Free (no host bar)
    & open to all
     
     

     
     
    or just show up 🙂

    Whether you would like to come debrief recent events or come discuss your latest startup project, the needs of your company (funding, advisors, people, CRO, IP attorney …), your latest scientific discovery (that you have of course already covered by a provisional), or just grab a TGIF drink and a glimpse of the sunset over the ocean with a bunch of international men & women of the San Diego biotech community, come join us at Bella V. .. and don’t worry, you don’t have to be French or speak French …

    Cheers 

     
     
    Company of the Month
     
     
    SOMMAILIER : a wine club created through 5 generations of French wine making experience
     
    For this month featured “company of the month”, we’d  like to introduce a newly created company here in San Diego,  SOMMAILIER! This is not yet another new microbrewery but   instead a brand new kind of boutique wine club 100% dedicated to French wines created by San Diego local and Bordeaux-native, Laurent Yung. He comes from five generations of French winemakers and has  access to exclusive, boutique French wines through his many connections in France. That’s the reason he started Sommailier – to share exclusive handcrafted wines that you can’t find in the U.S. with people who love French wine or want to learn more about it. Best part? The wine is shipped directly to your door every three months! And you can also send it as a gift to your wine lover friends or colleagues.Members will not only receive the bottles, but they will also receive education and information. Each bottle comes with a wine card providing information about the region it was grown and sourced, and the food pairing to accompany it. 
                                           
        
     
    Learn more about Sommailier and Laurent’s authentic story at www.sommailier.com. If you are interested in joining his club, you can use the code Biobeach20 and benefit from $20 off and free shipping on your first order. Feel free to contact him directly as well at laurent@sommailier.com if you have any question about his wine club.



      
     
     
     
    Events
     
     
     
    CRO Networking Mixer
    Please join on in the McGraw Boardroom at Biocom for a hosted CRO Networking Mixer specially designed for our CRO Members. With over a hundred CRO’s in our membership, this is an opportunity to gain a better understanding of your colleagues expertise in order to foster more collaboration within the CRO Community. 

    When?   November 7th 2017 5:00 pm to 7:00 pm
     
    Where? BIOCOM – McGraw Boardroom                            
    10996 Torreyana Road Suite 200
    San Diego, California  92121

     

    JLABS San Diego

    Meet with… Dementia Discovery Fund (DDF)
      
    Dementia is arguably the greatest single global healthcare challenge, affecting more than 47 million people worldwide at an estimated annual cost to the global economy of over US $604 billion…

    When? Tuesday, November 14th |
    10:30 AM to 5:00 PM
     
    Where? CONNECT
    4790 Eastgate Mall #125
     San Diego | California 92121       
           
     
     


                                                                                           
     
     

    BioLabs San Diego 

    “Bubbly and Blowouts”

     

    Join at the new drybar in La Jolla. This is a great event to network with other women in tech and biotech. Space is limited so book your spot and get your tickets.

     

    When?  Tuesday November 14th 2017

    4:00 PM – 7:00 PM


     

    Where?  Drybar La Jolla

    8867 Villa La Jolla Drive
    La Jolla, CA 92037                                

                        


                                           
     
    In the News
     
    • Thermo Fisher Scientific Signs Oncology Companion Diagnostic Development Agreement with Blueprint Medicines 
     
     
     
     
      MabVax Therapeutics Provides Update on the MVT-5873 Phase 1 Clinical Program and Expansion of Preclinical Development Pipeline at the AACR-NCI-EORTC International Conference
     
     
      Biotech Briefing: UC San Diego, Salk Scientists Awarded NIH Grants
     
     
     
     
     
    French BioBeach
    Ph: +1 (858) 215-2462 • www.frenchbiobeach.com

            

  • FBB october 2017 Newsletter





     
                 
                   
     
    Our newsletter keeps you in the loop of FBB’s News & Events. If for any reason you would like to  
    You are welcome to join us again at a later time
     
    BECOME A

     

     
    Thank You to our  Partners
     
     

    http://www.analytics-ventures.com/
     
     
     
     
     
     
     
     
     
     
     
     

     

    Big Thank You to our Sponsors & Members
     

     
     
     
     
     
     
     
     
     
     
     
     
     

     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     


     
    French BioBeach October 2017 Newsletter
     
    Dear French BioBeach community, 
     
    We have some great news for you… The FBB breakfast IS BACK! Thanks to our sponsor Antibody Design Labs you will have the opportunity to start this coming Tuesday with a delicious coffee and croissant 🙂
     
    This newsletter start with our FBB events. Our networking opportunities with our Breakfast and traditional Happy Hour rendez-vous.
     
    Then, our partner APL (American Preclinical Services) will be presented in the “Company of the Month” section. You will also find a link to apply for a Connected Intelligence Executive Circle organized by CLC.
     
    We end this exciting newsletter by some events and news we thought you might enjoy.
     
    Thanks to your support, we continue to monitor what happens in the Life Sciences community fostering new Partnering and Business Opportunities.
     
    The French BioBeach Team  Cool
     
    Upcoming French BioBeach Events
     
     
    Coffee & Croissants
     
    The FBB breakfast is back!!! 😀
       
    What’s best than a coffee and a croissant to start your tuesday properly?
        

    When? Tuesday October 3rd at 8:00am

     

    Where?  Antibody Design Labs
    Meeting in Coat-9, Conference center Union Station  –> Conference Room located next to “Come On In Cafe” @ 11120 Roselle St., Suite J San Diego, CA 92121

     

     Look for the French Flag…

     
     
     
     
     
     
     
     
     
    Monthly Happy Hour @ Bella Vista
     

    End of the week, Sunset & Happy Hour After Work? Join us for our Monthly (exeptionnaly the 3rd Friday of this month) Networking Happy Hours. 
     
    We look forward to seeing you there…!


    When? Friday, October 20th, from 5:00 to 7:00pm

     

    Where?  Bella Vista Social Club & Caffe, 2880 Torrey Pines Scenic Dr, La Jolla, CA 92037 

    Look for our French BioBeach sign!

     

     
     
     
     
     
    Free (no host bar)
    & open to all
     
     

     
     
     
    or just show up 🙂

    Whether you would like to come debrief recent events or come discuss your latest startup project, the needs of your company (funding, advisors, people, CRO, IP attorney …), your latest scientific discovery (that you have of course already covered by a provisional), or just grab a TGIF drink and a glimpse of the sunset over the ocean with a bunch of international men & women of the San Diego biotech community, come join us at Bella V. .. and don’t worry, you don’t have to be French or speak French …

    Cheers 

     
     
    Company of the Month
     
     
    The APS Preclinical Program: Your Path to Success

    Finding a reliable partner in the preclinical CRO space can be challenging. In the early stages of product development, having a partner you can trust and rely on is of paramount importance.
    Welcome to American Preclinical Services. APS is an AAALAC and ISO17025 accredited, USDA registered and GLP compliant preclinical center of excellence located in Minneapolis, MN.
    At APS, we have developed a comprehensive Powerful Preclinical Program to assist companies in meeting their R&D goals. The APS Preclinical Program includes regulatory, biocompatibility, interventional medical device, surgical medical device, analytical, physician training, bioskills, pathology, pharmacology, and toxicology services. 
     
    With this breadth of services under one roof, APS can advance your programs in all aspects of your product’s preclinical requirements. APS is adept at tailoring a Preclinical Program to fit your goals, with you and your team having direct collaborative control over study conduct and reporting timelines.

    Over 150 employees strong, the staff at APS have the scientific and technical expertise to guide your team in today’s fast paced and ever changing regulatory environment.  Whether you are conducting pilot evaluations, feasibility testing, or GLP studies, you will have industry experts to rely on every step of the way.
      
     
    Contact Information:
    Scott Barnhill, AS, SRS, RLATG 
    Business Development Executive 
    American Preclinical Services, LLC
    8945 Evergreen Blvd | Minneapolis, MN 55433
    Main Phone: 763-717-7990 | Direct Phone: 763-951-8990 | Mobile: 858-822-9648
    Direct Fax: 763-951-8991
    sbarnhill@apsemail.com
     
     
     
    Events
     
     
     
    CLC : 

    Connected Intelligence Executive Circle (SM)


    A virtual group coaching and networking experience like no other. By invitation or recommendation only


    All participants are sharp, supportive and interesting executives like you. Participants join each session via video conferencing from anywhere in the world, from any device, via private Zoom platform. 

    When?   Strating in October
     
    Where? video conferencing
     

    Confédération des Associations Centraliennes et Supelec
    Alumni Days Centrale(s) et Supélec 2017 à San Diego

    When? Thursday, July 20 2017 |

    4:00 pm – 7:00pm
    Where? Farmer & the Seahorse |
    10996 Torreyana Rd |
    San Diego, California 92121



     

                                                                                                             
     

    Charles River Presents : An Integrated Approach to Assess Drug-Induced Cardiovascular Liabilities

    Can we improve translation of preclinical data to clinical outcomes?


    Early in the drug development lifecycle, the process of evaluating compounds for hemodynamic and electrophysiological cardiovascular risk does not follow a regulated guideline, but more of an investigational method. Determining in-vitro assessments that translate to the whole animal and more importantly to the clinical outcome is paramount…

    When? 

    October 25, 2017 | 11:00 AM – 2:00 PM

     



    Where? 

    Green Acre | Campus Pointe 10300 Campus Point Drive | San Diego, CA 92121 Salon A


                                           
     
    In the News
     
     
    •  Drug from Sanford Burnham Prebys enters testing

     
     
     
    • International Stem Cell Corporation to Expand its Revenue Generating Biomedical Businesses to Support Ongoing and Future Clinical Trials

       

     
     
     
    LaughingThank you for reading!!         
     
     
    French BioBeach
    Ph: +1 (858) 215-2462 • www.frenchbiobeach.com

            

  • BIO Announces San Diego to Host the World’s Largest Industrial Biotechnology Conference in 2016

    Washington, DC (September 8, 2015) – The Biotechnology Industry Organization (BIO) today officially announced that logo_BIOthe 2016 World Congress on Industrial Biotechnology will be held April 17-20, 2016 in San Diego, California at the San Diego Convention Center. BIO is also announcing the call for papers for the event. Leaders from the biotechnology, bioenergy, chemical, consumer products manufacturing, and agricultural industries as well as academia and financial sectors are invited to submit proposals and individual papers beginning September 17, 2015.  

    “More than 400 biotechnology companies call San Diego their “home,” which makes it an exciting venue to host the world’s largest conference dedicated to promoting next-generation biobased products, renewable chemicals and biofuels,” stated Brent Erickson, Executive Vice President, Industrial and Environmental at BIO. “With California’s growing industrial biotech sector, BIO is excited to host the 2016 World Congress on Industrial Biotechnology in the center of it all.”

    The 2015 World Congress on Industrial Biotechnology, held in Montréal, drew 1,200 industry leaders from 725 companies, 50 countries and 37 states, as well as the District of Columbia. Further, the 2015 World Congress hosted more than 1,400 partnering meetings, a 40% increase from the 2014 BIO World Congress.

    The call for papers will open September 17 to invite submissions for breakout panels, breakout papers, posters, and Green Tech investor sessions. Leaders from the biotechnology industry, academia, and policy community are invited to offer an abstract or a proposal for a 15 minute presentation in any of the following program tracks:

    • Algae, Biomass Supply and Specialty Crops
    • Specialty Chemicals, Food & Nutritional Ingredients
    • Synthetic Biology and Genomics Research
    • Research Presentations
    • Technical Presentations
    • Renewable Chemicals and Biobased Materials
    • Advanced Biofuels and Biorefinery Platforms
    • Growing Global Biobased Markets

    Proposed papers and presentations should address any in a range of topics, including renewable chemicals, algae for fuels and bioproducts, and chemicals, biobased products, biomass utilization, cellulosic biofuels, metabolic engineering, new chemical pathways, regional economic development, synthetic biology, regulatory issues, new feedstock crops and feedstock sustainability, aviation biofuels, genetically engineered crops, project finance, biopathways to bulk chemicals, enzyme development, green plastics, work force training and specialty chemicals. 

    For more information on the conference or to submit a proposal, please visit http://www.bio.org/worldcongress

    For assistance, please contact worldcongress@bio.org.

  • Pathway Genomics Launches First Liquid Biopsy Test To Detect Cancer-Associated Mutations In High-Risk Patients

     
    pathway-logo1CancerIntercept-Detect-Monitor_header_-600x202

     

     

     

    SAN DIEGO – Sept. 10, 2015 – Pathway Genomics, a global precision medical diagnostics company, announced the launch of CancerInterceptTM, its first liquid biopsy, a non-invasive screening test designed for early cancer detection and monitoring, for as low as $299. 

     

    The test detects mutations that are commonly associated with lung, breast, ovarian, colorectal cancers and melanoma, as well as mutations that occur less frequently in other cancer types (such as pancreatic, head and neck, thyroid, gastric and prostate cancers). View an animation of howCancerIntercept works here.

    The test is offered for two general populations: CancerInterceptTM Detect is the first liquid biopsy designed to detect tumor DNA in high-risk but otherwise healthy patients; CancerInterceptTMMonitor monitors patients with active or previously diagnosed cancer. Both programs use advanced DNA analysis to identify small DNA fragments that are shed from cancer cells and released into the bloodstream. The tests analyze the presence of 96 frequently occurring DNA mutations in nine cancer genes.

    “Early detection is the single most important factor in ensuring successful treatments and improved survival rates,” said Jim Plante, CEO and founder of Pathway Genomics. “Cancer patients and those at risk for the disease can take proactive steps to safeguard their health and fight back against some of the most virulent forms of the disease.”

    In addition, with CancerIntercept Monitor, physicians are able to supplement more invasive tissue biopsies and scans with liquid biopsies to monitor cancer treatment efficacy, disease progression and recurrence. CancerIntercept Monitor can also be ordered with personalized Clinical Trial Matching for later stage cancer patients.

    “Rising levels of tumor DNA may indicate progression of the cancer before there is clinical or imaging evidence of tumor growth” said Dr. Glenn Braunstein, MD and Chief Medical Officer of Pathway Genomics. “Our liquid biopsy tests may also detect new mutations that occur over time and signal that the patient is becoming resistant to current therapy.”

    Testing can be initiated through the patient’s treating physician or through Pathway’s online physician referral network. For patients and physicians requesting repeat testing on a scheduled basis, a deeply discounted subscription service is available.

    CancerIntercept Detect and CancerIntercept Monitor are offered through Pathway’s integrated system, which streamlines the entire testing process from initial order to delivery of test reports. Key components of the system include physicians who will review online requisitions and order the tests; mobile phlebotomists to draw blood samples at the patient’s home or office; and Pathway’s medical oncology support team, who will discuss results with the patient’s treating physician upon a positive result. All positive results are released via the patient’s treating physician. Results are delivered approximately two to three weeks after testing.

    About Pathway Genomics

    Since its founding in 2008, Pathway Genomics has rapidly become a leader in the commercial healthcare industry. Pathway Genomics’ success lies in its commitment to deliver innovative healthcare solutions. The company’s program with IBM Watson is the first of its kind. The program is a smartphone app that merges artificial intelligence and deep learning with personal genetic information. The app provides users with personalized health and wellness information based on the individual’s health history.

    Based in San Diego, the company’s CLIA and CAP accredited clinical laboratory provides physicians and their patients in more than 40 different countries with actionable and accurate precision healthcare information to improve, or maintain, health and wellness. Pathway Genomics’ testing services cover a variety of conditions including cancer riskcardiac healthinherited diseasesnutrition and exercise response, as well as drug response for specific medications including those used in pain management and mental health. For more about Pathway Genomics, visit www.pathway.com or follow us on TwitterLinkedIn and Facebook.

     

    Read SD Union Tribune article:Sdut-logo

     

    New blood test helps detect cancer early

     

     

     

     

     

     

  • Celgene buys Receptos for $7.3 billion

     

    In one of the largest sales of a San Diego County biotech company to date, Receptos has agreed to a $7.32 billion cash purchase by Celgene, a New Jersey-based cancer drug maker with an office in San Diego.

    Celgene will gain a much-anticipated drug in clinical testing by Receptors for multiple sclerosis and ulcerative colitis. The drug, called ozanimod, is in a Phase 3 trial for relapsing multiple sclerosis.

    Formerly called RPC1063, the drug's potential has helped propel Receptos into becoming a multibillion-dollar company since its initial public offering in 2013. Receptos shares have surged more than fivefold over the last year as ozanimod progressed in clinical testing.

    The company agreed to pay $232 per share for Receptos, a 12 percent premium from Tuesday's closing price. The deal is expected to close this year.

    Receptos and Celgene valued the deal at $7.2 billion excluding Receptos' cash on hand. That's larger than all but a few local biotech purchases, the biggest of which was the $13.6 billion purchase of Carlsbad's Life Technologies by Thermo Fisher Scientific in 2014.

    Faheem Hasnain, Receptos' CEO, is highly regarded in the industry. Before Receptos, Hasnain led Facet Biotech, sold for $450 million cash to Abbott Laboratories in March 2010.

    Facet developed Zenapax, an injectable drug for multiple sclerosis. The Receptos drug is taken orally.

    Celgene, based in Summit, New Jersey, employs several hundred people in San Diego, said spokesman Greg Geissman. The workforce performs early stage research on identifying potential new drugs.

    "We're very excited about this," Geissman said. "This is a great opportunity for us to continue to bolster this inflammation and immunology franchise."

    Receptos has 68 employees, according to a profile on Yahoo Finance. Celgene is interested in keeping Receptos employees, but it's not clear how many will be retained, Geissman said.

    Receptos reported about $2 billion in first-quarter sales of its drugs, which include the multiple myeloma treatments Revlimid and Pomalyst and breast and lung cancer drug Abraxane.

    Revlimid, its top seller, is also used to treat severe anemia and mantle cell lymphoma.

    The purchase of Receptos is part of a push to boost its sales of treatments for inflammatory and immune diseases. In 2014 Celgene launched its first drug in that category, the psoriasis and psoriatic arthritis treatment Otezla.

    Receptos doesn't have any approved drugs on the market. The company expects results from late-stage trials of ozanimod in 2017 and 2018 and hopes to get the drug approved as a treatment for multiple sclerosis in 2018.

    In addition to ulcerative colitis, Receptos is also studying ozanimod as a treatment for inflammatory bowel disease. The companies said they think its annual sales could reach $6 billion.

    In extended trading, Receptos shares added 10 percent, or $21.17, to $228.35. The stock closed at $37.75 a year ago.

    Celgene shares rose nearly 6 percent, or $7.07, to $129.92 in late trading. Last month Celgene agreed to invest about $1 billion in drug developer June Therapeutics Inc., mostly by buying stock. The companies plan to develop cancer and autoimmune disease treatments.

    Source: UT San Diego By Bradley J. Fikes | 7:10 p.m. July 14, 2015

  • Illumina Non-Invasive verifi® Prenatal Test May Reflect Presence of Maternal Cancer

    Study of Illumina's Non-Invasive verifi® Prenatal Test Suggests that Test Results, When Discordant from Fetal Karyotyping, May Reflect Presence of Maternal Cancer

    — Results Published in Journal of the American Medical Association —

    SAN DIEGO–(BUSINESS WIRE)–

    Illumina, Inc. (ILMN) today announced that a preliminary study retrospectively correlated 10 cases of occult maternal cancer among pregnant women receiving an “aneuploidy detected” or “aneuploidy suspected” positive results on the verifi® noninvasive Prenatal Test (NIPT)1 to discordant results of fetal karyotypes for the women, suggesting that discordant NIPT test results may be indicative of maternal cancer.

    Maternal cancers sometimes leave tell-tale abnormal cell free DNA fragments in plasma. In 8 of 10 reported cancer cases, Illumina scientists and physicians reviewed all the genome-wide sequencing data and identified nonspecific copy-number changes across multiple chromosomes, suggesting that these changes, when present in a woman whose fetal karyotype tests as normal, might represent a signal to the clinician to probe for the presence of cancer.

    The results of the study, entitled “Noninvasive Prenatal Testing and Incidental Detection of Occult Malignancies,” are available online today in The Journal of the American Medical Association and the full article can be accessed at broadcast.jamanetwork.com. The paper will be included in the July 14 print edition of JAMA.

    “Abnormal tumor DNA, shed from maternal malignancies, can cause highly unusual NIPT results, including the findings of more than one chromosome abnormality detected,” commented Diana W. Bianchi, M.D., Executive Director of the Mother Infant Research Institute at Tufts Medical Center, and lead author of the publication. “All abnormal NIPT results should be confirmed with a diagnostic test, such as amniocentesis or chorionic villus sampling (CVS). If there is a difference between the fetal diagnostic test and the NIPT results, maternal cancer can be a rare but important underlying explanation. In order to provide the best maternal clinical care, this possibility should be considered, especially when multiple abnormalities of chromosome number are identified on the NIPT report.”

    In a retrospective analysis of 125,426 noninvasive verifi® Prenatal Tests, 3,757 (three percent) were positive for one or more aneuploidies involving chromosomes 13, 18, 21, X or Y. As part of Illumina’s standard procedures, the laboratory contacts the referring physician to discuss all positive test results and to recommend a diagnostic procedure to obtain a confirmatory fetal karyotype. From this group of 3757 positive cases, 10 cases of maternal cancers were subsequently (between 3 and 39 weeks after NIPT) reported to the laboratory. At the time of NIPT these women were not diagnosed with cancer. In 3 cases the abnormal NIPT findings prompted a search for an underlying malignancy. Seven of these eight women had diagnostic tests that indicated a chromosomally-normal fetus, discordant with the NIPT test result. One woman did not undergo a diagnostic procedure.

    Maternal cancers were most frequently associated with the rare NIPT finding of multiple aneuploidies that were discordant with the fetal karyotype. The cancer types were clinically diverse, including three cases of B cell lymphoma and single cases of T-cell leukemia, Hodgkin’s lymphoma, unspecified adenocarcinoma, leiomyosarcoma, and neuroendocrine, colorectal and anal carcinomas. The cancers ranged from stage II to metastatic disease (IV). In one case, after completion of treatment, the abnormal DNA signature became undetectable in follow-up testing.

    “This study shows that NIPTs that use whole genome sequencing techniques may have the ability to detect some cancer signatures under certain conditions,” said Dr. Rick Klausner, Illumina’s Chief Medical Officer. “The sensitivity and specificity of the verifi Prenatal Test to detect cancer is not currently known, and further studies will be required to develop a test for this specific purpose. We have published these results to help clinicians improve overall patient care by considering the possibility of maternal cancer if there is discordance between positive NIPT results and a normal fetal karyotype. We also want to encourage health care providers to contact the clinical sequencing laboratory with follow-up information on abnormal NIPT results that show concordance as well as discordance with fetal karyotype, including cancers diagnosed in pregnant women, so that we can better understand the nonspecific patterns of DNA changes that precede clinical symptoms.”

    About the verifi® Prenatal Test

    The Illumina verifi® Prenatal Test analyzes genetic material (cfDNA) from a pregnant woman’s blood to look for too few or too many copies of chromosomes in the mother and baby, or babies in the case of twins. Missing or extra copies of chromosomes are referred to as “aneuploidies” and may be related to conditions in pregnancy such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) or sex chromosome (X and Y) associated conditions.

    Source: Results from Journal of the American Medical Association, published by BusinessWire

  • IPC & Innate Pharma collaborate on Translational Research for Novel Immune Checkpoint Inhibitors

    IPC, The comprehensive Cancer Center of Marseille, and Innate Pharma collaborate on Translational Research for Novel Immune Checkpoint Inhibitors

    The Paoli Calmettes Institute (IPC), a private not-for-profit comprehensive cancer center in Marseille, France, has initiated a collaboration with Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), a biopharmaceutical company based in Marseille, to conduct translational research aimed at identifying specific populations of patients with hematological cancers who may benefit most from treatment with Innate Pharma’s novel proprietary antibodies, and to identify associated biomarkers.

    innate-logoNicolai Wagtmann, Chief Science Officer of Innate Pharma, said: “This agreement strengthens our translational research capabilities, at the core of our drug development process. IPC is a leading center in hematology-oncology with deep understanding in immunology and capabilities in immune monitoring. Early-stage testing of Innate Pharma’s promising antibodies on patient samples will greatly optimize subsequent clinical development by better identifying the most relevant indications, patient populations and biomarkers”.

    logo-ipc-bigPr. Patrice Viens, Chief Executive Officer of IPC, stated that “This new R&D collaboration with Innate Pharma further expands a long-lasting relationship which started with lirilumab, a fully human monoclonal antibody blocking the interaction between Killer-cell immunoglobulin-like receptors (KIR) on NK cells with their ligands on tumor cells. IPC conducted the “first-in-man study” of lirilumab and continues to be involved in the development of this drug. IPC and Innate Pharma are also involved in other partnerships within the frame of the Marseille SIRIC* and of Marseille Immunopole **”.

    The collaboration will operate under the direction of Pr. Daniel Olive, Head of the Immunity and Cancer research team and of the immune monitoring platform at IPC, and Pascale André, Senior Director, R&D, at Innate Pharma. It will also involve drug-discovery research teams and experts in translational research at IPC, including Pr. Norbert Vey and Pr. Anthony Gonçalvès, and other scientists with expertise in converting promising drug discoveries into clinical treatments for cancer patients.

    Under the terms of the collaboration agreement, IPC will test Innate Pharma’s new therapeutic antibodies in immuno-oncology using IPC’s extensive biological resource collection. Innate Pharma’s antibodies are designed to block immune checkpoints, one of the most promising classes of drugs in oncology. These immune checkpoints interfere with the natural defense mechanisms of our immune system against cancer and regulate immunosuppressive mechanisms. Their blockade can unleash the patient’s immune system to recognize and eliminate cancer cells. However, only a fraction of patients respond to current immune checkpoint inhibitors, and identifying the population of patients most likely to respond to various checkpoint blockers would be of great interest. This R&D collaboration will facilitate the development of novel therapeutic antibodies by identifying the best suited patient population and indications for a given drug.

    * The Marseille SIRIC is the site for integrated cancer research focused on breast cancer, leukemia and myelodystrophy, glioma and pancreatic cancer funded by the French National Cancer Institute, which brings together   IPC, the Assistance Publique – Hôpitaux de Marseille (AP-HM) and their associated research centers.

    ** Marseille Immunopole is a unique collaborative ecosystem for therapeutic innovation in immunology, integrating all the skills from academic to clinic. It aims to make Marseille the European capital of the R&D of immune-based therapy

  • AN UNEXPECTED SURPRISE: EUROPE TO MOVE AWAY FROM FDA-STYLE APPROVAL PROCESS FOR MEDICAL DEVICES

    European FlagsLast week provided breaking news in regards to a highly anticipated and much-talked about topic – the future of the medical device approval process in Europe.

    The 2011 breast implant controversy, where the French company PIP produced defective breast implants made from cheap industrial silicone, has since put the Medical Device Approval process in the EU under the microscope. As a result of this scrutiny, many had raised the question of whether a European-wide, “FDA” style approval process should be adopted for medical devices.

    With the unforeseen leak of the draft report from the Council of Europe on June 11th, it seems that the answer behind a proposal for centralisation is now a resounding ‘no.’ The proposed regulation  put forward by the Latvian presidency and corroborated by many of the Member States discussed the placing, making available and putting into service medical devices on the market. This will be seen as welcome news for American companies seeking EU commercialisation while they are undergoing the arduous FDA process.

    CE-markFor quite some time, it had been suggested that EU institutions should look into ways that would help tighten safety of medical devices. Some lawmakers had therefore felt that in order to solve the problem of a lax EU system, Europe needed a model which resembles the FDA; a US-centralized approval model rather than the current decentralized one, where each country sets its own legal and safety requirements, would be the only answer.

    It seems that leaving the decision and approval process in the hands of Notified Authorities is still plausible. As stated in Article 28 of the proposed regulation “a member state that intends to designate a conformity assessment body as a notified body […] to carry out conformity assessment activities […] shall nominate an authority […] for the assessment, designation and notification” of medical devices.

    This is further reiterated in Annex VIII allowing the nominated authority to still oversee and work with notified bodies, who will in turn work with manufacturers on the approval process.

    The outlined proposals in Chapter VI in regards to clinical evaluations and investigations also stress a more thorough process with the addition that “the Commission, in collaboration with the Member States, shall […] set up, manage and maintain an electronic system”.

    The discussions that took place on June 19th were set to begin the formal review of the proposal into the Trilogue between the Commission, EU Parliament and Member States.

    Although it may seem at first glance an approach to allow the ‘old ways’, it actually paves a way into making a leap from the current directive into differentiating itself from the pharmaceutical industry so that it is, in its own right, specific for medical devices.

    The proposal does not ‘shy away’ from a centralized system because of bureaucracy or financial implications, but merely that a bulky process like that of the FDA is not necessarily the correct model for the EU. It instead provides a means for tighter regulations without necessarily adding delays to its nimble approval process.

    Going forward, the Trilogue will most likely begin in September for proposed adoption by mid-2016 and full implementation in all Member States by 2019.

    SOURCE: http://www.medeuronet.com/medeuronet/an-unexpected-surprise-europe-to-move-away-from-fda-style-approval-process-for-medical-devices/

    June 22, 2015  by Dr. Sunni Patel, medeuronet clinical scientist